Chronic lymphocytic leukemia is one of the most common types of leukemia in adults. It belongs to the group of indolent lymphoproliferative disorders and has a slow clinical course. Approximately 50% of newly diagnosed patients do not require treatment for years. A better understanding of the pathophysiology of the disease has led to the development of models for assessment of the risk.
Introduction
Chronic lymphocytic leukemia (CLL) is a disease characterized by a variable clinical course [1] . The advanced stages. Patients are also divided into three groups, using Rai staging system (clinical-topographic) and Binet (laboratory) for evaluating the risk as low, intermediate and high. The aggressive course of the disease is usually associated with advanced clinical stages (III, IV Rai /C-Binet), large tumor mass, high lactate dehydrogenase levels and diffuse bone marrow classical" prognostic factors. Over the years, with the introduction of more precise and detailed methods of laboratory evaluation, new biological prognostic markers were weight protein present in all nucleated cells, and it is a part of the major histocompatibility described in 1968 by Berggard in patients with Wilson's disease [5] . Low levels of beta-2 microglobulin in physiological condition healthy individuals [3, 6, 7] . Typically, the and catabolized in the proximal tubules [7, 8] . Elevated serum marker values are described in kidney disease associated with glomerular damage, autoimmune and malignant diseases, and viral infections [8] . In cases of malignant hematological diseases, the serum marker is used as a single prognostic factor in patients with malignant lymphoproliferative disorders and is part of the accepted international staging system (ISS) in multiple myeloma patients [9] . Longin follicular lymphoma patients [10] . In medical reviews, B2M correlates with the clinical stages of B-CLL [2] .
CD49d belongs to the group of integrins and, together with B-cell receptor (BCR), Toll-like receptors, cytokines and chemokines it supports the cell-cell, cell-matrix interactions and helps the proliferative activity of lymphocytes [11] . It takes part in the formation of macromolecular complexes in the lipid rafts of the B-cell membrane with CD38, CD44, and . CD49d is a phenotypic marker, whose high expression is related to poor prognosis [12] . According to medical reviews, the high levels of expression of the marker above 30% indicate that treatment is to be started [13] .
Materials and Methods
To B-CLL diagnosis, as well as to distinguish CD49d positive patients cytometric analysis of peripheral blood of 30 patients was carried out, using FAC Sort/ 
Results
We present the results of patients with diagnosis B-CLL, meeting the revised criteria of IWGCLL from 2008. All patients signed an informed consent, approved by the ethics committee of MU-Pleven. The cohort included early-stage patients (0, I, II Rai). Ten milliliters of blood was used to evaluate immunological marker and serum level of B2M. Levels of CD49d over 30% were accepted as positive in CD19 positive B-lymphocytes. Levels of B2M higher than 2.34 mg/l were interpreted as pathologic.
The study included 30 patients -12 (40%) females and 18 (60%) males. The average age of the patients was 66.7 (41-84). The distribution of patients by age is presented in Figure 1 .
Out of 29 patients (in one of the included patients the immunological marker was not tested), CD49d was positive only in eight of them. Four (25.0%) of them were in stage O-Rai, two in stage I, and two (28.6%) were in stage II. The distribution of the patients according to stages and CD49d is shown in Table 1 .
The test of independence (cross tabulation) was applied to determine whether there was an association between the stage of the disease and CD49dwas applied. The analysis showed In one of all the 30 patients, B2M was not tested. To avoid compromising the results, since most of the patients were over 50 years of age; all the patients included in the study were evaluated for additional creatinine clearance. Ten of the early stage patients had serum levels of B2M above the normal range. In 19 individuals, the result was within the standard limits. No was found in the early stage B-CLL patients (Phi
Discussion
The results of our study showed that a small number of patients in the early stages of the disease had an elevated beta-2 microglobulin level, and even fewer had high levels of CD49d in combination with beta-2 microglobulin. disease (Binet A), only 73 (32%) had serum marker levels above the reference range. In the same cohort, which was followed for 3.5 years, just in 55 patients (32%), it was necessary to start treatment [14] . In our study, out of the 29 patients tested for a serological marker, the B2M was higher than the reference range only in 10 of them. Sarris et al. (2013) investigated the clinical light chains in patients with B-CLL. They also relationship between beta-2 microglobulin level and commencement of treatment [15] .
We studied a correlation between the stage of the disease and the levels of CD49d expression as a factor related to the migration of lymphocytes from the blood circulation and their retention in the secondary lymphatic structures. Only eight out of a total of 29 early-stage patients by Baumann et al. (2016) , whose study showed that high levels of CD49d expression were found only in 30% of early stage (0, I-II) patients [16] .
Conclusions
The results of our study showed that a small number of patients in the early stages of the disease had high levels of beta-2 microglobulin and CD49d. The extent to which these two indicators are relevant to the time to treatment is to be studied in the longer-term follow-up in the affected group of patients, as well as in patients who at an advanced stage and have not been correlation between B2M and CD49d could be due to the small number of cases we studied.
